Januvia and Hyperhidrosis - a phase IV clinical study of FDA data

Summary:

Hyperhidrosis is reported as a side effect among people who take Januvia (sitagliptin phosphate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Metformin, and have High blood pressure.

The phase IV clinical study analyzes which people have Hyperhidrosis when taking Januvia. It is created by eHealthMe based on reports of 71,642 people who have side effects when taking Januvia from the FDA, and is updated regularly.

What is Januvia?

Januvia has active ingredients of sitagliptin phosphate. It is often used in diabetes. eHealthMe is studying from 72,818 Januvia users. Check the latest studies of Januvia.

What is Hyperhidrosis?

Hyperhidrosis (abnormally increased sweating) is found to be associated with 2,550 drugs and 3,547 conditions by eHealthMe. Check the latest studies of Hyperhidrosis.

On Jul, 18, 2026

71,642 people reported to have side effects when taking Januvia.
Among them, 585 people (0.82%) have Hyperhidrosis.

Among these 585 people:

* Approximation only. Some reports may have incomplete information.

Do you take Januvia and have Hyperhidrosis?

- Check whether Hyperhidrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Januvia:

Januvia (72,818 reports)

Hyperhidrosis treatments and more:

Hyperhidrosis (147,206 reports)

How severe was Hyperhidrosis and when was it recovered:

Hyperhidrosis in Januvia

Expand to all the drugs that have ingredients of sitagliptin phosphate:

Hyperhidrosis and drugs with ingredients of sitagliptin phosphate (596 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Januvia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperhidrosis:

Hyperhidrosis (2,550 drugs)

Browse all the conditions that are associated with Hyperhidrosis:

Hyperhidrosis (3,547 conditions)

Related publications that referenced our studies

Liao KF, Lin CL, Lai SW, Chen WC, "Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: a population-based case-control study in Taiwan", European journal of internal medicine, 2016 Jan .
Belice T, Yuce S, Kizilkaya B, Kurt A, Cure E, "Noncardiac pulmonary edema induced by sitagliptin treatment", Journal of family medicine and primary care, 2014 Jan .
Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .
Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP, "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia?)", Dermatology online journal, 2012 Feb .
Liao KF, Lin CL, Lai SW, Chen WC, "Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: a population-based case-control study in Taiwan", European journal of internal medicine, 2016 Jan .
Belice T, Yuce S, Kizilkaya B, Kurt A, Cure E, "Noncardiac pulmonary edema induced by sitagliptin treatment", Journal of family medicine and primary care, 2014 Jan .
Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .
Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP, "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia?)", Dermatology online journal, 2012 Feb .

How the study uses the data?

The study uses data from the FDA. It is based on sitagliptin phosphate (the active ingredients of Januvia) and Januvia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.